|
WO2016097036A1
|
|
Estrogen receptor ligand for use in treating melanoma
|
|
CN105960236A
|
|
Estrogen receptor beta agonists for use in treating mesothelioma
|
|
GB201417456D0
|
|
Treatment of cancer
|
|
GB201417465D0
|
|
Treatment of cancers
|
|
GB201406939D0
|
|
Screening method
|
|
GB201321531D0
|
|
Treatment for cancers
|
|
GB201308893D0
|
|
Screening method
|
|
GB201301896D0
|
|
Novel Estrogen Receptor Ligands
|
|
GB201211233D0
|
|
Screening method
|
|
WO2012022776A1
|
|
Substituted thiopenes or furans as estrogen receptor ligands
|
|
GB201113538D0
|
|
Novel estrogen receptor ligands
|
|
HK1152039A1
|
|
Novel estrogen receptor ligands
|
|
GB201105984D0
|
|
Novel estrogen receptor ligands
|
|
GB201105979D0
|
|
Novel estrogen receptor ligands
|
|
GB201105983D0
|
|
Novel estrogen receptor ligands
|
|
GB201105224D0
|
|
Novel pharmaceutical compositions
|
|
GB201018113D0
|
|
Use of an estrogen receptor ligang for treating disease
|
|
GB201018112D0
|
|
Use of an estrogen receptor ligand for treating disease
|
|
CN102791688A
|
|
Estrogen receptor ligands
|
|
CN102648183A
|
|
Substituted pyrazoles as estrogen receptor ligands
|
